Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Anbogen Raises $12.5 Million to Develop Precision Oncology Portfolio

publication date: Feb 5, 2024

Anbogen Therapeutics, a Taipei clinical-stage prevision oncology company, raised $12.5 million in a Series A funding round. to advance its two lead drug candidates, ABT-101 and ABT-301. Both candidates were supported by Taiwan’s National Research Program for Biopharmaceuticals (NRPB) before they were acquired by Anbogen. ABT-101 is a HER2-targeting tyrosine kinase inhibitor, and ABT-301 is a novel small molecule drug that potentiates efficacy of immune checkpoint inhibitors. Anbogen’s A round was led by China Development Industrial Bank with participating from Taian Venture Capital, Maxpro and the National Development Fund. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital